Unit:
Κατεύθυνση Κλινικοπαθολογοανατομική θεώρηση των νεοπλασιών του ανθρώπουLibrary of the School of Health Sciences
Supervisors info:
Περικλής Φούκας, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, Ε.Κ.Π.Α. (Επιβλέπων)
Ιωάννης Γ. Παναγιωτίδης, Καθηγητής, Ιατρική Σχολή, Ε.Κ.Π.Α.
Πηνελόπη Κορκολοπούλου, Καθηγήτρια, Ιατρική Σχολή, Ε.Κ.Π.Α.
Original Title:
Μελέτη του μεταγραφικού παράγοντα MEF2C σε διάχυτα από μεγάλα Β κύτταρα λεμφώματα
Translated title:
Study of the transcription factor MEF2C in diffuse large B cell lymphomas
Summary:
Background: Diffuse large B-cell lymphomas (DLBCL) are the most common subtype of non-Hodgkin's lymphomas. However, the pathogenesis of DLBCL is not fully understood. Transcription factors or signaling pathways implicated in normal B lymphocytes function may be the basis for future therapeutic targets. Such transcription factor is MEF2C (Myocyte-specific enhancer factor 2C) contributing to the activation of the lymphoid lineage and the formation of the germinal center.
Methods: 82 patients with DLBCL were enrolled in our study. We evaluated the expression of MEF2C by performing immunohistochemistry on paraffin slides of 62 tissue blocks from our patients. We used the semi-quantification method of H score. We analyzed the clinical, laboratory and pathologic characteristics of patients in relation to overall survival (OS), disease free survival (DFS) and the expression of MEF2C.
Results: Mean and median value of MEF2C H score was 120±58. We observed a significant correlation with age (p= 0.021) and a tendency to correlate with lactate dehydrogenase (LDH) (p = 0.18). The expression of MEF2C was not associated with stage, Ιnternational Prognostic Index (IPI) and its variants, laboratory values, presence of B symptoms, origin and expression of Ki 67 and BCL6. MEF2C positivity>80% correlated with borderline non-significant difference in OS (p = 0.083). Finally, patients with OS more than 12 months and MEF2C H score>120 had a significant worse OS comparing with those with MEF2C H score<120 (p = 0.009).
Conclusion: Patients with higher expression of MEF2C showed a trend of worse overall survival compared to patients with lower expression of MEF2C. However, these results should be confirmed in larger groups of DLBCL patients and the underlying oncogenic mechanism of MEF2C in DLBCL should be further explored
Main subject category:
Health Sciences
Keywords:
Lymphomas, Transcription factor MEF2C, Ιmmunohistochemistry, H score, Ki 67
